Compounding Chemotherapy Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Compounding Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs), By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Compounding Chemotherapy Market is set to expand from USD 5.31 Billion in 2025 to USD 7.21 Billion by 2031, demonstrating a 5.23% CAGR. This market focuses on creating personalized antineoplastic medications in sterile environments, precisely tailored to individual cancer patients' unique dosing and formulation needs based on their physiological parameters, moving beyond standardized fixed-dose regimens. Growth is primarily driven by the increasing global cancer incidence and a rising clinical preference for precision medicine, which demands customized therapeutic protocols for optimal efficacy and toxicity management. Furthermore, the growing geriatric population's need for flexible dosage adjustments significantly sustains market demand.
Market Driver
The expanding global incidence and prevalence of cancer serve as a fundamental catalyst for the growth of the compounding chemotherapy market. As the demographic burden of oncological diseases intensifies, there's a corresponding surge in the clinical demand for antineoplastic treatments that commercial mass production cannot always meet. Compounding pharmacies play a critical role in providing tailored solutions, especially for patients requiring precise dosage adjustments based on body surface area or specialized formulations. According to the World Health Organization in February 2025, cancer remains a leading global cause of death, accounting for nearly 10 million fatalities, underscoring the vast patient volume requiring flexible and accessible chemotherapy options. Concurrently, persistent shortages of commercially available chemotherapy drugs significantly increase reliance on outsourcing and specialized compounders. When conventional pharmaceutical supply chains encounter disruptions, hospitals turn to 503B compounding facilities for essential medications, such as cisplatin and carboplatin, to ensure continuous patient care. Data from Penn Medicine in December 2024 revealed that prescription rates for specific chemotherapy agents dropped by 15.1% during peak supply disruptions, highlighting the volatility of commercial access and driving substantial growth for compounding entities capable of mitigating these shortfalls. Fagron's March 2025 Annual Report noted a 17% increase in REBITDA, directly attributing this growth to robust demand for their compounding services, bolstered by ongoing drug shortages.
Market Challenge
Supply chain instability, particularly concerning raw materials and sterile injectables, represents a significant hurdle for the expansion of the compounding chemotherapy sector. Compounding facilities heavily depend on a consistent flow of specific antineoplastic agents to prepare personalized regimens. When global manufacturing consolidates or quality control issues interrupt production at major active pharmaceutical ingredient (API) facilities, compounding pharmacists face immediate inventory deficits. This inability to procure base ingredients leads to operational slowdowns, hindering facilities from delivering the precise dosage adjustments that constitute their primary value proposition, thereby undermining the core advantage of the compounding model. The persistence of these shortages directly limits market throughput and revenue potential; for instance, the European Association of Hospital Pharmacists reported in late 2025 that nearly 64% of surveyed hospital pharmacists experienced patient therapy delays due to medicine shortages, with oncology drugs being among the most frequently affected. Such unpredictability forces healthcare providers to ration care or revert to standard fixed-dose alternatives to maintain treatment continuity. Consequently, the market's growth is constrained as the inability to ensure a reliable and continuous supply compromises the trust and consistency vital for time-sensitive cancer treatments.
Market Trends
The widespread adoption of robotic compounding automation is fundamentally transforming the sector by enhancing the precision of sterile preparations and significantly reducing healthcare worker exposure to hazardous antineoplastic agents. Hospitals and specialized pharmacies are increasingly integrating automated workflows to minimize human error in complex volumetric calculations and to safely contain cytotoxicity risks within controlled environments. This technological shift is evidenced by the growing penetration of advanced verification systems, with the American Society of Health-System Pharmacists reporting in May 2024 that technologies assisting sterile product preparation are utilized in 62.8% of hospitals, highlighting the critical transition toward automated safety protocols. Simultaneously, the market is experiencing substantial growth in home-based chemotherapy infusion services, driven by a shift towards patient-centric care models that prioritize convenience and aim to reduce hospitalization costs. This trend alleviates the logistical burden on busy oncology centers and allows immunocompromised patients to receive essential treatments in lower-risk home environments. The escalating demand for these remote care capabilities is reflected in the financial performance of major providers; for example, Option Care Health reported a 16.2% net revenue increase for the full year 2024, attributing this surge to the expanded utilization of home and alternate site infusion therapies.
Key Market Players
* Pfizer Inc.
* Baxter International Inc.
* Grifols SA
* Comecer S.P.A.
* Arxium Inc.
* Dedalus Group
* B. Braun Melsungen AG
* Omnicell Technologies Inc.
* The Metrix Company
* Sterline S.R.L
Report Scope
In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Compounding Chemotherapy Market, By Drug Type
* Cytotoxic Drugs
* Hormonal Agents
* Immunomodulatory Agents
* Targeted Therapies
* Supportive Care Drugs
# Compounding Chemotherapy Market, By Route of Administration
* Intravenous
* Oral
* Subcutaneous
* Intramuscular
* Intrathecal
# Compounding Chemotherapy Market, By Cancer Type
* Breast Cancer
* Lung Cancer
* Colorectal Cancer
* Prostate Cancer
* Leukemia
* Lymphoma
# Compounding Chemotherapy Market, By Distribution Channel
* Hospital Pharmacies
* Retail Pharmacies
* Online Pharmacies
# Compounding Chemotherapy Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.
Available Customizations:
Global Compounding Chemotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Compounding Chemotherapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Compounding Chemotherapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Cancer Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Compounding Chemotherapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Cancer Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Compounding Chemotherapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Cancer Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Compounding Chemotherapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Cancer Type
6.3.3.2.4. By Distribution Channel
7. Europe Compounding Chemotherapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Cancer Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Compounding Chemotherapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Cancer Type
7.3.1.2.4. By Distribution Channel
7.3.2. France Compounding Chemotherapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Cancer Type
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Cancer Type
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Compounding Chemotherapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Cancer Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Compounding Chemotherapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Cancer Type
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Compounding Chemotherapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Cancer Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Compounding Chemotherapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Cancer Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Compounding Chemotherapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Cancer Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Compounding Chemotherapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Cancer Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Compounding Chemotherapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Cancer Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Compounding Chemotherapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Cancer Type
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Compounding Chemotherapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Cancer Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Compounding Chemotherapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Cancer Type
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Compounding Chemotherapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Cancer Type
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Compounding Chemotherapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Cancer Type
9.3.3.2.4. By Distribution Channel
10. South America Compounding Chemotherapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Cancer Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Compounding Chemotherapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Cancer Type
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Compounding Chemotherapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Cancer Type
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Compounding Chemotherapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Cancer Type
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Compounding Chemotherapy Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Baxter International Inc.
15.3. Grifols SA
15.4. Comecer S.P.A.
15.5. Arxium Inc.
15.6. Dedalus Group
15.7. B. Braun Melsungen AG
15.8. Omnicell Technologies Inc.
15.9. The Metrix Company
15.10. Sterline S.R.L
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們